Skip to main content

News

FOQUEST® RECEIVES APPROVAL FOR EXPANDED INDICATION FOR CHILDREN AND ADOLESCENTS WITH ADHD

Published on March 12, 2019

First and only methylphenidate product approved in Canada that provides control of ADHD symptoms throughout…

Read More

Klaria signs exclusive development, license and supply agreements with Purdue Pharma (Canada) for the emergency treatment of anaphylactic reactions (KL-01401)

Published on January 22, 2019

Klaria signs exclusive development, license and supply agreements with Purdue Pharma (Canada) for the emergency…

Read More

BETADINE® – A NEW TREATMENT OPTION FOR CANADIANS FOR ORAL INFECTIONS – NOW AVAILABLE IN CANADA

Published on September 4, 2018

PICKERING, ON, September 4, 2018 – Purdue Pharma (Canada) announces today that BETADINE® Sore Throat…

Read More

PURDUE PHARMA (CANADA) APPOINTS ANDRÉ CÔTÉ VICE PRESIDENT, HEALTH SOLUTIONS

Published on May 22, 2018

PICKERING, ON, May 22, 2018 /CNW/ — André Côté is appointed Vice President, Health Solutions…

Read More

ARCHIVE

2019
2018
2017
2016
2015
2014
2013
2012

For all media inquiries, please contact:

media@purdue.ca

↓